肌层浸润性尿路上皮膀胱癌患者新辅助帕博利珠单抗对比顺铂为基础化疗或直接根治性膀胱切除术的疗效比较
本研究比较新辅助帕博利珠单抗后根治性膀胱切除术(RC)与顺铂为基础新辅助化疗(NAC)后RC或直接RC的疗效,按顺铂合格性分别分析。顺铂不合格者中帕博利珠单抗组3年无事件生存(EFS)为77.8%,直接RC组为36.1%;顺铂合格者中帕博利珠单抗组3年EFS为86.9%,NAC组为63.5%,逆概率治疗加权后EFS仍更优。结果受研究回顾性性质限制。
要点
- 顺铂不合格患者中,帕博利珠单抗后RC的3年EFS为77.8%,直接RC为36.1%(p<0.001)。
- 顺铂合格患者中,帕博利珠单抗后RC的3年EFS为86.9%,NAC后RC为63.5%(p<0.001)。
- 帕博利珠单抗组病理缓解率和RC后无复发生存(RFS)也优于NAC组。
核心结论
- 在首次报告的新辅助ICI与NAC后RC或直接RC的全面比较中,作者报告新辅助ICI在MIBC患者中反应增加、肿瘤学结局改善。
研究设计与样本
- 对顺铂合格和顺铂不合格的cT2-4N0M0 MIBC患者分别进行两项分析,采用基于逆概率治疗加权(IPTW)的倾向性评分调整。
- 帕博利珠单抗组来自PURE-01试验,NAC后RC或直接RC组来自高容量三级转诊中心。
- 共分析2005年10月至2020年10月在Moffitt癌症中心接受RC(伴或不伴NAC)的458例患者和PURE-01试验入组的146例患者。
主要发现
- 顺铂不合格患者中,帕博利珠单抗后RC组EFS优于直接RC组(p<0.001);估计3年EFS为帕博利珠单抗后RC组77.8%(95%CI 63.5-95.2)vs 直接RC组36.1%(95%CI 28.6-45.5)。
- 顺铂不合格患者IPTW后,接受新辅助ICI(NICI)者EFS仍更优(p<0.001)。
- 顺铂合格患者中,帕博利珠单抗后RC组EFS优于NAC组(p<0.001);估计3年EFS为帕博利珠单抗组86.9%(95%CI 80.9-93.3)vs NAC组63.5%(95%CI 56.5-71.4)。
- 顺铂合格患者IPTW后,接受NICI者EFS仍更优(p<0.001)。
- 帕博利珠单抗治疗患者的病理缓解率和RC后RFS也优于NAC治疗患者。
临床怎么用
- 作者报告新辅助ICI在MIBC患者中反应增加、肿瘤学结局改善,并预期可能设定新的治疗标准,但需等待正在进行的随机研究结果。
局限性
- 结果受研究的回顾性性质限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent progresses in the use of immune checkpoint inhibitor (ICI) have challenged the therapeutic standards in patients with muscle-invasive urothelial bladder carcinoma (MIBC). OBJECTIVE: To compare neoadjuvant pembrolizumab followed by radical cystectomy (RC) versus neoadjuvant chemotherapy (NAC) and RC or upfront RC, according to cisplatin eligibility. DESIGN, SETTING, AND PARTICIPANTS: We conducted two separate analyses for cisplatin-eligible and cisplatin-ineligible cT2-4N0M0 MIBC patients. We used a propensity score adjustment that relied on inverse probability of treatment-weighting (IPTW). INTERVENTION: Pembrolizumab within the PURE-01 trial, and NAC and RC or upfront RC from a high-volume tertiary care referral center. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint in both analyses was event-free survival (EFS), defined as freedom from recurrence, and/or death from any cause indexed from the date of treatment initiation or RC. The secondary endpoints included EFS in propensity score-matched patients, pathologic response rate, and recurrence-free survival (RFS) after RC. RESULTS AND LIMITATIONS: A total of 458 patients who underwent RC, with or without NAC, at Moffitt Cancer Center between October 2005 and October 2020, and 146 patients enrolled in PURE-01 were analyzed. In cisplatin-ineligible patients, EFS was superior in those receiving pembrolizumab (p < 0.001). The estimated 3-yr EFS was 77.8% (95% confidence interval [CI]: 63.5-95.2) for pembrolizumab and RC, and 36.1% (95% CI: 28.6-45.5) for upfront RC. EFS remained superior in those receiving neoadjuvant ICI (NICI) following IPTW (p < 0.001). In cisplatin-eligible patients, EFS was superior in those receiving pembrolizumab and RC (p < 0.001). The estimated 3-yr EFS was 86.9% (95% CI: 80.9-93.3) for pembrolizumab and 63.5% (95% CI: 56.5-71.4) for NAC. EFS remained superior in those receiving NICI following IPTW (p < 0.001). Pathologic responses and RFS in pembrolizumab-treated patients were also superior to those in NAC-treated patients. Results are limited by the retrospective nature of the study. CONCLUSIONS: In the first ever reported comprehensive comparison of outcomes between neoadjuvant ICI and NAC, followed by RC, or upfront RC, we report increased responses and improved oncologic outcomes with neoadjuvant ICI in patients with MIBC. PATIENT SUMMARY: We compared the results obtained from the use of pembrolizumab and radical cystectomy with standard-of-care treatments in patients with bladder carcinoma infiltrating the muscle layer. We reported increased response and survival rates possibilities with the use of immunotherapy, anticipating the possibility to set new therapeutic standards in these patients, pending the results of ongoing randomized studies.
引用
- Li R, Nocera L, Rose KM, et al. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024. PMID: 38184473. doi:10.1016/j.euo.2023.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。